Media stories about Clearside Biomedical (NASDAQ:CLSD) have been trending somewhat positive on Wednesday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Clearside Biomedical earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.7904885677138 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- Clearside BioMedical, Inc. (CLSD) – Unusual Volume Activity on Watch List – Wall Street Morning (wallstreetmorning.com)
- Clearside Biomedical (CLSD) Upgraded by BidaskClub to “Hold” (americanbankingnews.com)
- Clearside BioMedical, Inc. (CLSD) sticks almost 84.92% in last 5 trades – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Clearside BioMedical, Inc. (CLSD) – Lookout Watch Unusual Volume stock – Wall Street Morning (wallstreetmorning.com)
- Active Stock Evaluation – Clearside BioMedical Inc (NASDAQ: CLSD) – Alpha Beta Stock (alphabetastock.com)
CLSD has been the subject of a number of research analyst reports. Zacks Investment Research raised Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Friday, December 8th. Wedbush reaffirmed a “buy” rating on shares of Clearside Biomedical in a report on Wednesday, February 7th. Needham & Company LLC upped their price target on Clearside Biomedical from $18.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, March 6th. JMP Securities reaffirmed an “outperform” rating and issued a $25.00 price target on shares of Clearside Biomedical in a report on Monday, March 5th. Finally, ValuEngine downgraded Clearside Biomedical from a “sell” rating to a “strong sell” rating in a report on Monday, February 5th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $19.50.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3260985/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-clearside-biomedical-clsd-share-price.html.
About Clearside Biomedical
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.